Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - The market remains volatile, particularly in the tech sector, leading to cautious sentiment among investors [2] Group 2 - The article emphasizes the importance of performing due diligence and drawing personal conclusions before making investment decisions [4] - Seeking Alpha highlights that past performance does not guarantee future results and that opinions expressed may not reflect the views of the platform as a whole [5]

Group 1 - Rising interest rates, concerns over tariffs on Canadian oil imports, and oversupply of energy have negatively impacted the REIT (VNQ) and energy production (XLE) sectors recently [1] Group 2 - Samuel Smith has extensive experience in dividend stock research and leads the High Yield Investor investing group, focusing on safety, growth, yield, and value [2]

Core Viewpoint - Alexandria Real Estate Equities, Inc. has announced a public offering of $550 million in senior notes with a 5.50% interest rate, maturing in 2035, to refinance existing debt and for general corporate purposes [1][2][3] Group 1: Offering Details - The notes are priced at 99.733% of the principal amount, yielding 5.532% to maturity [2] - The offering is managed by a consortium of financial institutions including Goldman Sachs, BofA Securities, and Citigroup [1] - The closing of the sale is expected around February 13, 2025, subject to customary conditions [2] Group 2: Use of Proceeds - Net proceeds will be used to redeem or repay the Company's 3.45% Senior Notes due April 30, 2025 [3] - Any excess proceeds will be allocated for general working capital and corporate purposes, including debt repayment and property development [3] Group 3: Company Background - Alexandria is a leading life science REIT, established in 1994, focusing on collaborative ecosystems in major life science innovation clusters [6] - The company is recognized as a best-in-class operator and developer in the life science real estate sector [6]

Group 1 - The leader of the investing group High Yield Landlord shares a real-money REIT portfolio and transactions in real-time, featuring three portfolios: core, retirement, and international [1] - Jussi Askola, President of Leonberg Capital, is a value-oriented investment expert with a focus on consulting hedge funds, family offices, and private equity firms on REIT investing [1] - Askola has authored award-winning academic papers on REIT investing and has established relationships with many top REIT executives [1] Group 2 - The article does not provide any specific financial data or performance metrics related to the companies or the industry [2][3]

Group 1 - Aecon Group Inc. has completed the collaborative development phase and reached commercial close on a progressive design-build transit project [1] - The implementation phase will commence under a target price contract, with Aecon's share of the contract valued at over $2.8 billion [1] - This contract will be added to Aecon's Construction segment backlog in the first quarter of 2025 [1] Group 2 - Aecon Group Inc. is a North American construction and infrastructure development company with global experience [2] - The company provides integrated solutions to private and public-sector clients through its Construction segment in various sectors including Civil, Urban Transportation, Nuclear, Utility, and Industrial [2] - Aecon also offers project development, financing, investment, management, and operations and maintenance services through its Concessions segment [2]

Alexandria Real Estate Equities, Inc. (ARE) reported fourth-quarter 2024 adjusted funds from operations (AFFO) per share of $2.39, meeting the Zacks Consensus Estimate. The reported figure outpaced the year-ago quarter’s AFFO per share of $2.28 by 4.8%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Results reflected a rise in revenues, aided by decent leasing activity and rental rate growth. However, higher interest expenses year over year undermined the results to some extent. Ale ...

For the quarter ended December 2024, Alexandria Real Estate Equities (ARE) reported revenue of $788.95 million, up 4.2% over the same period last year. EPS came in at $2.39, compared to -$0.54 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $789.14 million, representing a surprise of -0.03%. The company has not delivered EPS surprise, with the consensus EPS estimate being $2.39.While investors scrutinize revenue and earnings changes year-over-year and how they compar ...

Alexandria Real Estate Equities (ARE) came out with quarterly funds from operations (FFO) of $2.39 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $2.28 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this life science real estate company would post FFO of $2.38 per share when it actually produced FFO of $2.37, delivering a surprise of -0.42%.Over the last four quarters, the company has surpassed consensus FFO estimat ...

Accessibility Statement Skip Navigation Alexandria Real Estate Equities, Inc. All rights reserved. ©2025 (PRNewsfoto/Alexandria Real Estate Equities, Inc.) Alexandria Real Estate Equities, Inc. All rights reserved. ©2025 (PRNewsfoto/Alexandria Real Estate Equities, Inc.) Alexandria Real Estate Equities, Inc. All rights reserved. ©2025 (PRNewsfoto/Alexandria Real Estate Equities, Inc.) Alexandria Real Estate Equities, Inc. All rights reserved. ©2025 (PRNewsfoto/Alexandria Real Estate Equities, Inc.) ...

Company Highlights Alexandria highlights its competitive advantages, strong financial performance, and robust balance sheet, driven by its Megacampus™ platform and leadership in the life science industry [Competitive Advantages & Megacampus™ Platform](index=3&type=section&id=Competitive%20Advantages%20%26%20Megacampus%E2%84%A2%20Platform) Alexandria highlights its competitive strengths, including its pioneering role in the life science real estate sector and its focus on a Megacampus™ platform, central to its strategy for superior operating results - The company emphasizes its key competitive advantages: a large, high-quality laboratory platform, a diverse client base of approximately **800 tenants**, a strong balance sheet, and an experienced management team[6](index=6&type=chunk) Megacampus™ Platform Concentration (as of Dec 31, 2024) | Metric | Percentage | | :--- | :--- | | Annual Rental Revenue | 77% | | Operating RSF | 71% | | Total Development and Redevelopment Pipeline RSF | 68% | - Alexandria's Megacampus properties have demonstrated superior performance, with an average occupancy of **96% since 2020**, outperforming non-megacampus properties by **4%**[9](index=9&type=chunk) [Financial Performance & Shareholder Value](index=4&type=section&id=Financial%20Performance%20%26%20Shareholder%20Value) The company showcases strong, consistent growth in Funds From Operations (FFO) per share, outperforming its peers and translating into outstanding long-term total shareholder return since its 1997 IPO - Alexandria has demonstrated strong five-year growth in **FFO per share (diluted, as adjusted) from 2019 to 2024**, surpassing the average of its healthcare REIT peers[12](index=12&type=chunk)[13](index=13&type=chunk) - Since its IPO on May 27, 1997, to December 31, 2024, Alexandria has delivered a total shareholder return of **2,801%**, significantly outperforming peers like Welltower and the broader MSCI US REIT Index[14](index=14&type=chunk)[15](index=15&type=chunk) [Internal Growth & Operational Excellence](index=6&type=section&id=Internal%20Growth%20%26%20Operational%20Excellence) Alexandria's internal growth is driven by strong leasing activity, high and stable occupancy, and a high-quality, diverse tenant base, evidenced by solid 2024 leasing volume and consistent rent collections - **2024 leasing volume reached 5.1 million RSF**, a **19% increase** over the 2014–2020 annual average of 4.3 million RSF[18](index=18&type=chunk)[19](index=19&type=chunk) - **Q4 2024 leasing volume was 1.3 million RSF**, up **19%** over the preceding five-quarter average of 1.1 million RSF[20](index=20&type=chunk)[21](index=21&type=chunk) - The company maintains a high-quality tenant base of approximately **800 tenants**, with **92% of top 20 tenant annual rental revenue** from investment-grade or large-cap tenants. Tenant rent collections have averaged **99.8% from Q1 2021 to Q4 2024**[25](index=25&type=chunk)[26](index=26&type=chunk)[27](index=27&type=chunk) [Balance Sheet & Capital Strategy](index=9&type=section&id=Balance%20Sheet%20%26%20Capital%20Strategy) The company emphasizes its 'fortress balance sheet,' characterized by low leverage, significant liquidity, and a well-staggered debt maturity profile, supported by strategic dispositions and a growth-oriented dividend strategy Key Balance Sheet Metrics (as of Dec 31, 2024) | Metric | Value | | :--- | :--- | | Net Debt and Preferred Stock to Adjusted EBITDA | 5.2x | | Significant Liquidity | $5.7 billion | | Weighted-Average Remaining Debt Term | 12.7 years | | Weighted-Average Interest Rate | 3.86% | | Average % of Fixed-Rate Debt (since 2020) | 98.4% | - Alexandria executed a successful capital recycling strategy, completing **$1.4 billion in dispositions in 2024**. From 2019-2024, total dispositions and partial interest sales amounted to **$9.6 billion**, generating a net gain of **$2.9 billion**[31](index=31&type=chunk)[39](index=39&type=chunk) Dividend Highlights (4Q24) | Metric | Value | | :--- | :--- | | Dividend per Common Share | $1.32 | | Dividend Yield | 5.4% | | Payout Ratio | 55% | | Average Annual Dividend Per-Share Growth (2020-2024) | 5.4% | [Industry and Corporate Responsibility Leadership](index=12&type=section&id=Industry%20and%20Corporate%20Responsibility%20Leadership) Alexandria positions itself at the forefront of the $5.5 trillion life science industry, driven by strong secular growth and a commitment to corporate responsibility, aiming for positive impact on human health and society - The company operates at the center of the secularly growing **$5.5 trillion life science industry**[40](index=40&type=chunk)[41](index=41&type=chunk) - The report highlights a strong trend of **FDA approvals for novel therapies and innovative medicines**, underpinning the demand for life science real estate[42](index=42&type=chunk)[43](index=43&type=chunk) Earnings Press Release This section details Alexandria's financial and operating results for Q4 and FY2024, provides 2025 guidance, and summarizes acquisition and disposition activities, along with consolidated financial statements [Financial and Operating Results (4Q24 & FY2024)](index=15&type=section&id=Fourth%20Quarter%20and%20Year%20Ended%20December%2031%2C%202024%20Financial%20and%20Operating%20Results) For Q4 2024, Alexandria reported a net loss per share of ($0.38) and FFO per share, as adjusted, of $2.39, reflecting solid leasing, positive rental growth, and strong capital strategy execution Key Financial Results | Metric (per share, diluted) | 4Q24 | 2024 | | :--- | :--- | :--- | | Net (Loss) Income | $(0.38) | $1.80 | | FFO, as adjusted | $2.39 | $9.47 | 2024 Leasing and Rental Rate Performance | Metric | Value | | :--- | :--- | | Total Leasing Activity | 5,053,954 RSF | | Rental Rate Increase (Renewals/Re-leasing) | 16.9% | | Rental Rate Increase (Cash Basis) | 7.2% | - The company executed its 2024 capital plan, which included **$1.4 billion in funding from strategic dispositions**, with **$1.1 billion completed in Q4 2024**[51](index=51&type=chunk)[52](index=52&type=chunk) - Development and redevelopment projects placed into service in 2024 are expected to generate **$118 million in incremental annual net operating income**. The total pipeline is expected to deliver an additional **$395 million by Q2 2028**[53](index=53&type=chunk) [Guidance (2025)](index=16&type=section&id=Guidance) Alexandria projects 2025 FFO per share (diluted, as adjusted) between $9.23 and $9.43, with key assumptions including year-end occupancy of 91.6% to 93.2% and $1.2 to $2.2 billion in dispositions 2025 Guidance Highlights | Metric | Midpoint/Range | | :--- | :--- | | FFO per Share, as adjusted | $9.23 to $9.43 ($9.33 midpoint) | | EPS, diluted | $2.57 to $2.77 | | Year-End Occupancy | 91.6% to 93.2% | | Same Property NOI (Cash Basis) | (1.0)% to 1.0% | | Dispositions and Sales of Partial Interests | $1.7 billion (midpoint) | | Construction Spending | $1.75 billion (midpoint) | - The guidance for dispositions was increased by **$150 million** to reflect transactions expected in Q4 2024 that are now anticipated to close in 2025[68](index=68&type=chunk) - As of January 27, 2025, the company has **$539.5 million in pending dispositions** under negotiation, representing about **32% of the guidance midpoint**[73](index=73&type=chunk) [Acquisitions (2024)](index=17&type=section&id=Acquisitions) In 2024, Alexandria completed acquisitions totaling $249.4 million, with the most significant being a 60% interest in Dorchester Avenue properties in Greater Boston for future development 2024 Key Acquisitions | Property | Submarket/Market | Purchase Price (in millions) | | :--- | :--- | :--- | | 285, 299, 307, and 345 Dorchester Avenue (60% interest) | Seaport Innovation District/Greater Boston | $155.3 | | 428 Westlake Avenue North | Lake Union/Seattle | $47.6 | | **Total 2024 Acquisitions** | | **$249.4** | [Dispositions (2024 & 2025 Outlook)](index=17&type=section&id=Dispositions) The company completed $1.38 billion in dispositions in 2024, with a significant portion in Q4, and has a 2025 disposition guidance range of $1.2 to $2.2 billion, with $539.5 million already identified in pending transactions 2024 Dispositions Summary | Period | Sales Price (in millions) | | :--- | :--- | | YTD 3Q24 | $238.7 | | 4Q24 | $1,143.7 | | **Total 2024** | **$1,382.5** | - Major Q4 2024 dispositions included One Moderna Way in Greater Boston for **$369.4 million** and a portfolio of properties in Cambridge for **$245.5 million**[77](index=77&type=chunk) - For 2025, the company has **$227.9 million in pending dispositions** with non-refundable deposits and an additional **$421.3 million** subject to letters of intent or negotiations[78](index=78&type=chunk) [Consolidated Financial Statements](index=19&type=section&id=Consolidated%20Financial%20Statements) This section provides the detailed, unaudited consolidated financial statements for the periods ended December 31, 2024, including the Statements of Operations, Balance Sheets, and the reconciliation of Net Income to Funds From Operations (FFO) [Consolidated Statements of Operations](index=19&type=section&id=Consolidated%20Statements%20of%20Operations) For the year ended December 31, 2024, total revenues were $3.12 billion, with net income attributable to common stockholders significantly increasing to $309.6 million, or $1.80 per diluted share, despite a Q4 net loss due to impairment Annual Statement of Operations Highlights (in millions) | Line Item | 2024 | 2023 | | :--- | :--- | :--- | | Total Revenues | $3,116.4 | $2,885.7 | | Total Expenses | $2,688.9 | $2,687.3 | | Gain on Sales of Real Estate | $129.3 | $277.0 | | Net Income Attributable to Common Stockholders | $309.6 | $92.4 | [Consolidated Balance Sheets](index=19&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2024, Alexandria reported total assets of $37.5 billion, with $32.1 billion in real estate investments, total liabilities of $15.1 billion, and total equity of $22.4 billion Balance Sheet Summary (as of Dec 31, in billions) | Line Item | 2024 | 2023 | | :--- | :--- | :--- | | Investments in Real Estate | $32.1 | $31.6 | | Total Assets | $37.5 | $36.8 | | Total Liabilities | $15.1 | $14.1 | | Total Equity | $22.4 | $22.6 | [Funds From Operations (FFO) and FFO per Share](index=20&type=section&id=Funds%20From%20Operations%20and%20Funds%20From%20Operations%20per%20Share) For the full year 2024, FFO attributable to common stockholders was $1.43 billion, or $8.32 per diluted share, with FFO, as adjusted, reaching $1.63 billion, or $9.47 per diluted share, and Q4 2024 FFO per share, as adjusted, at $2.39 FFO Reconciliation Summary (Year Ended Dec 31, 2024) | Metric (in millions) | Amount | | :--- | :--- | | Net Income Attributable to Common Stockholders | $309.6 | | Depreciation and Amortization of Real Estate | $1,191.5 | | Gain on Sales of Real Estate | $(127.6) | | Impairment of Real Estate | $192.5 | | **FFO Attributable to Common Stockholders** | **$1,431.8** | | Adjustments (Unrealized losses, impairments, etc.) | $197.3 | | **FFO, as adjusted** | **$1,629.1** | FFO Per Share - Diluted, As Adjusted | Period | Per Share Amount | | :--- | :--- | | 4Q24 | $2.39 | | Full Year 2024 | $9.47 | | Full Year 2023 | $8.97 | Supplemental Information This section provides detailed company and investor information, financial and asset base highlights, insights into client base and internal growth, external growth strategies, balance sheet management, and definitions with reconciliations of key financial metrics [Company and Investor Information](index=22&type=section&id=Company%20and%20Investor%20Information) This section details Alexandria's mission as a life science REIT, its pioneering role in Megacampus™ ecosystems, and provides information on its executive management and equity research analysts - Alexandria pioneered the life science real estate niche and is the preeminent owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations[98](index=98&type=chunk) - The company highlights its high-quality, diverse tenant base, with **52% of annual rental revenue** from investment-grade or publicly traded large-cap companies[100](index=100&type=chunk) - The executive and senior management team consists of **62 individuals** with an average of **24 years of real estate experience**, including **13 years with Alexandria**[102](index=102&type=chunk) [Financial and Asset Base Highlights](index=23&type=section&id=Financial%20and%20Asset%20Base%20Highlights) This section presents a detailed quarterly breakdown of key financial data, operating statistics, and capital expenditure information from Q4 2023 to Q4 2024, highlighting trends in operating margin, Adjusted EBITDA, and leverage ratios Key Metrics (as of Dec 31, 2024) | Metric | Value | | :--- | :--- | | Total Market Capitalization | $29.0 billion | | Total Equity Capitalization | $16.8 billion | | Net Debt and Preferred Stock to Adjusted EBITDA (Quarter Annualized) | 5.2x | | Fixed-Charge Coverage Ratio (Quarter Annualized) | 4.3x | | Occupancy of Operating Properties - North America | 94.6% | - General and administrative expenses as a percentage of net operating income (trailing 12 months) improved to **7.6% in Q4 2024** from **9.8% in Q4 2023**[110](index=110&type=chunk) [Client Base & Occupancy](index=24&type=section&id=Client%20Base%20%26%20Occupancy) Alexandria emphasizes stable cash flows from its high-quality, diverse tenant base, with 52% of annual rental revenue from investment-grade tenants, long-duration lease terms, and consistently high occupancy rates, especially in Megacampus properties - **52% of the company's annual rental revenue** is from investment-grade or publicly traded large-cap tenants, and **92% of the top 20 tenants' revenue** falls into this category[112](index=112&type=chunk) Lease Term and Collections (as of Dec 31, 2024) | Metric | Value | | :--- | :--- | | Weighted-Average Remaining Lease Term (All Tenants) | 7.5 years | | Weighted-Average Remaining Lease Term (Top 20) | 9.3 years | | 4Q24 Tenant Collections (as of Jan 27, 2025) | 99.9% | | Jan 2025 Tenant Collections (as of Jan 27, 2025) | 99.5% | - The company has maintained a solid historical average occupancy of **96% over the past 10 years** for its operating properties[113](index=113&type=chunk) [Internal Growth](index=26&type=section&id=Internal%20Growth) This section details Alexandria's internal growth drivers, including same-property performance, robust leasing activity of over 5 million RSF in 2024 with positive rental rate increases, and a high-quality, well-staggered tenant base [Same Property Performance](index=26&type=section&id=Same%20Property%20Performance) For the year ended December 31, 2024, same-property net operating income (NOI) increased by 1.2% and by 4.6% on a cash basis, demonstrating steady growth from the core portfolio Same Property NOI Growth vs. Prior Year | Period | NOI Change | NOI Change (Cash Basis) | | :--- | :--- | :--- | | Q4 2024 | 0.6% | 6.3% | | Year 2024 | 1.2% | 4.6% | [Leasing Activity](index=26&type=section&id=Leasing%20Activity) In 2024, Alexandria leased a total of 5,053,954 RSF, achieving a 16.9% rental rate increase (7.2% cash basis) on renewed and re-leased space, with an 8.5-year weighted-average lease term Leasing Activity (Year Ended Dec 31, 2024) | Metric | Renewed/Re-leased Space | | :--- | :--- | | RSF | 3,888,139 | | Rental Rate Change | 16.9% | | Rental Rate Change (Cash Basis) | 7.2% | | Weighted-Average Lease Term | 8.5 years | [Contractual Lease Expirations](index=27&type=section&id=Contractual%20Lease%20Expirations) The company presents a well-staggered lease expiration schedule, with 10.0% of occupied RSF expiring in 2025, providing long-term visibility into cash flows through 2034 and beyond Lease Expiration Schedule by Year | Year | % of Occupied RSF Expiring | % of Annual Rental Revenue Expiring | | :--- | :--- | :--- | | 2025 | 10.0% | 8.2% | | 2026 | 7.7% | 6.9% | | 2027 | 8.9% | 8.6% | | 2028 | 10.7% | 9.5% | | 2029 | 6.5% | 5.9% | [Top 20 Tenants](index=27&type=section&id=Top%2020%20Tenants) Alexandria's top 20 tenants, predominantly high-quality, investment-grade entities like Eli Lilly and Moderna, account for 35.4% of annual rental revenue with a weighted-average remaining lease term of 9.3 years - The top 20 tenants represent **35.4% of total annual rental revenue**, with a weighted-average remaining lease term of **9.3 years**[125](index=125&type=chunk) - **92% of the annual rental revenue from the top 20 tenants** is from investment-grade or publicly traded large-cap companies[124](index=124&type=chunk) [External Growth / Investments in Real Estate](index=32&type=section&id=External%20Growth%20%2F%20Investments%20in%20Real%20Estate) This section details Alexandria's external growth strategy, centered on its development and redevelopment pipeline, which is expected to generate $395 million in incremental annual net operating income from projects delivering between Q1 2025 and Q2 2028, alongside details on construction spending and joint ventures [Investments in Real Estate Overview](index=32&type=section&id=Investments%20in%20Real%20Estate%20Overview) Alexandria's future growth is significantly driven by its development and redevelopment pipeline, with projects placed into service in 2024 adding $118 million in annual net operating income, and an additional $395 million projected from 2025 through Q2 2028 Future Growth from Development/Redevelopment Pipeline | Period | Incremental Annual NOI | RSF / Status | | :--- | :--- | :--- | | Placed in Service 2024 | $118M | 1.5M RSF (98% Occupied) | | Expected 2025 | $83M | 89% Leased/Negotiating | | Expected 1Q26 – 2Q28 | $312M | 4.4M RSF | - The total development and redevelopment pipeline (under construction and future opportunities) spans **30.2 million RSF**, with a gross book value of **$8.9 billion**[143](index=143&type=chunk) [New Class A/A+ Development and Redevelopment Properties](index=33&type=section&id=New%20Class%20A%2FA%2B%20Development%20and%20Redevelopment%20Properties) This sub-section provides a comprehensive look at the company's development and redevelopment activities, detailing recent deliveries in 2024, current projects under construction, and highlighting that 68% of the total pipeline RSF is within Megacampus™ ecosystems - In 2024, the company delivered **2.46 million RSF** of development/redevelopment projects with a total investment of **$4.28 billion**, achieving a weighted-average initial stabilized yield of **6.7%**[145](index=145&type=chunk)[146](index=146&type=chunk) - As of December 31, 2024, there are **4.36 million RSF of projects under construction**, with a total estimated investment of **$7.51 billion**. These projects are **45% leased/negotiating**[154](index=154&type=chunk)[158](index=158&type=chunk) - The total development and redevelopment pipeline (under construction, priority, and future) amounts to **30.2 million RSF**, with a book value of **$8.6 billion**[172](index=172&type=chunk) [Construction Spending and Capitalization of Interest](index=39&type=section&id=Construction%20Spending%20and%20Capitalization%20of%20Interest) For the year ended December 31, 2024, total construction spending was $2.02 billion, with a projected midpoint of $1.75 billion for 2025, primarily allocated to active projects and pre-construction work for Megacampus expansions Construction Spending (in millions) | Period | Total Spending | | :--- | :--- | | Year Ended Dec 31, 2024 | $2,018 | | Projected Year Ending Dec 31, 2025 (Midpoint) | $1,750 | - The company has **$684.1 million in projected capital contribution commitments** from existing real estate joint venture partners to fund construction from 2025 through 2028[175](index=175&type=chunk) [Joint Venture Financial Information](index=40&type=section&id=Joint%20Venture%20Financial%20Information) Alexandria utilizes consolidated and unconsolidated joint ventures to manage its portfolio and fund development, with the noncontrolling interest share of consolidated JVs valued at $4.49 billion and the company's share of unconsolidated JVs at $39.9 million as of December 31, 2024 Joint Venture Equity (as of Dec 31, 2024) | JV Type | Value | | :--- | :--- | | Noncontrolling Interest Share of Consolidated JVs | $4.49 billion | | Our Share of Unconsolidated Real Estate JVs | $39.9 million | - For the year ended Dec 31, 2024, the noncontrolling interest share of FFO from consolidated JVs was **$312.5 million**, and the company's share of FFO from unconsolidated JVs was **$8.0 million**[191](index=191&type=chunk)[246](index=246&type=chunk) [Balance Sheet Management](index=41&type=section&id=Balance%20Sheet%20Management) This section provides a deep dive into Alexandria's balance sheet, highlighting its non-real estate investments, strong credit profile with $5.7 billion in liquidity, and a debt portfolio characterized by a long weighted-average term and high fixed-rate percentage [Investments (Non-Real Estate)](index=41&type=section&id=Investments%20(Non-Real%20Estate)) Alexandria holds a non-real estate investment portfolio, primarily in life science companies, with a carrying amount of $1.48 billion as of December 31, 2024, resulting in a net loss of $53.1 million for 2024 Non-Real Estate Investment Portfolio (as of Dec 31, 2024) | Metric | Value | | :--- | :--- | | Cost Basis | $1.21 billion | | Carrying Amount | $1.48 billion | | Unrealized Gains | $228.1 million | | Unrealized Losses | $(144.5) million | [Key Credit Metrics](index=41&type=section&id=Key%20Credit%20Metrics) The company highlights its strong credit position with significant liquidity of $5.7 billion as of December 31, 2024, maintaining healthy credit ratios such as Net Debt and Preferred Stock to Adjusted EBITDA at 5.2x and a Fixed-Charge Coverage Ratio of 4.3x Liquidity (as of Dec 31, 2024, in millions) | Component | Amount | | :--- | :--- | | Availability under unsecured senior line of credit | $5,000 | | Cash, cash equivalents, and restricted cash | $560 | | Other | $152 | | **Total Liquidity** | **$5,712** | [Summary of Debt](index=42&type=section&id=Summary%20of%20Debt) As of December 31, 2024, Alexandria had total debt of $12.2 billion, characterized by a weighted-average remaining term of 12.7 years, a weighted-average interest rate of 3.86%, and 98.8% fixed-rate debt, with significant cushion on all debt covenants Debt Composition (as of Dec 31, 2024) | Metric | Value | | :--- | :--- | | Total Debt | $12.24 billion | | Fixed-Rate Debt | 98.8% | | Variable-Rate Debt | 1.2% | | Weighted-Average Remaining Term | 12.7 years | | Weighted-Average Interest Rate | 3.86% | - The company is in compliance with all debt covenants, with key ratios such as **Total Debt to Total Assets at 29%** (vs. ≤60% requirement) and **Secured Debt to Total Assets at 0.4%** (vs. ≤40% requirement)[210](index=210&type=chunk) [Definitions and Reconciliations](index=44&type=section&id=Definitions%20and%20Reconciliations) This section provides definitions for key terms and non-GAAP financial measures, including Adjusted EBITDA, FFO, and NOI, along with detailed reconciliations to their GAAP counterparts, ensuring transparency and aiding investor analysis - Provides definitions for non-GAAP measures including **Adjusted EBITDA**, **Funds From Operations (FFO)**, **Net Operating Income (NOI)**, and others[219](index=219&type=chunk) - Includes detailed reconciliation tables for key non-GAAP measures like **Adjusted EBITDA from Net Income**, **FFO from Net Income**, and **NOI from Net Income**[220](index=220&type=chunk)[246](index=246&type=chunk)[268](index=268&type=chunk) - Explains the methodology behind key operating metrics such as **annual rental revenue**, **capitalization rates**, **same property comparisons**, and **investment-grade tenant classification**[225](index=225&type=chunk)[226](index=226&type=chunk)[252](index=252&type=chunk)[275](index=275&type=chunk)